TrueWealth by TrueData – Live AI Summaries & Real-Time BSE/NSE Corporate Announcements
Copyright © TrueWealth 2025
Made with in INDIA
TrueData – Authorized Market Data Vendor for NSE, BSE, MCX (Official Logo)
Latest AnnouncementsToday 0
Upcoming Events
News Feed

  • No Data Found

P

Pfizer Ltd

PFIZER

pfizerltd.co.in NSE PFIZER BSE500680 ISIN: INE182A01018
₹4664.5
-0.48% (-22.30)
Website

pfizerltd.co.in

NSE
NSE

PFIZER

BSE
BSE

500680

ISIN

INE182A01018

Announcement Post Market Close
General :: Newspaper Publication
Aug 04 2026, 04:58:37 PM

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Advertisement - Special Window for Re- lodgement of Transfer and Dematerialisation of Physical Securities.

Pfizer Ltd
Since 1950

Pfizer Ltd is a leading pharmaceutical company in India and a subsidiary of the global Pfizer Inc. , headquartered in New York. Established in 1950, the company operates with a strong legacy of innovation and is focused on the development, manufacture, and marketing of prescription medicines across multiple therapeutic areas including cardiology, neurology, vaccines, oncology, and women’s health.

Sector
Pharmaceuticals Sector
Recent Announcements (…Last 3 Days)
P
04 Aug 2026•16:58:37
General::Newspaper Publication
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Advertisement - Special Window for Re- lodgement of Transfer and Dematerialisation of Physical Securities.

truewealth
Request an update
Pfizer Ltd
Pharmaceuticals SectorSince 1950
About

Pfizer Ltd is a leading pharmaceutical company in India and a subsidiary of the global Pfizer Inc. , headquartered in New York. Established in 1950, the company operates with a strong legacy of innovation and is focused on the development, manufacture, and marketing of prescription medicines across multiple therapeutic areas including cardiology, neurology, vaccines, oncology, and women’s health.

With its principal manufacturing facility located in Goa and a nationwide distribution and sales network, Pfizer Ltd has a well-entrenched presence in the Indian pharmaceutical sector, serving both private and public healthcare segments.

As one of India's prominent MNC pharma players, Pfizer Ltd leverages cutting-edge R&D from its global parent while maintaining a compliant and quality-focused approach to operations. The company's product portfolio features both globally patented medicines and several well-known legacy brands that hold leadership positions in their respective categories.

Business Model & Strategy

Pfizer Ltd generates revenues primarily through the marketing and sale of prescription pharmaceuticals. Its business model is built on in-licensing patented products from its parent and global affiliates, as well as the development and commercialization of branded generics tailored for the Indian market. The company emphasizes a robust distribution network, partnerships with healthcare professionals, and expansion into high-growth therapy segments like oncology and vaccines.

Strategic growth drivers include regular new product launches, driving market penetration of existing portfolios, digital engagement initiatives, and selective collaborations with other multinationals and local companies. Pfizer Ltd also maintains a focus on compliance, cost optimization, and operational efficiency to protect margins amid evolving regulatory and competitive landscapes.

Management Overview
8 Members
Mr.Pradip Shah
Non-Executive - Non Independent Director-Chairperson
Ms.Meena Ganesh
Non-Executive - Independent Director
Mr.Lakshmanan Krishnakumar
Non-Executive - Independent Director
Ms.Sonia Singh
Non-Executive - Independent Director
Ms.Meenakshi Nevatia
Executive Director-CEO-MD
Mr.Amit Agarwal
Executive Officer & Chief Financial Officer
Mr.P Rengan
Executive Director
PrajeetNair
Company Secretary and Compliance Officer
Awards & Recognition
5 Awards
  • Featured in ET 500 Top Companies 2024
  • Recognized as a 'Top Employer India 2024' by the Top Employers Institute
  • Received Silver in the 'Best Corporate Social Responsibility (CSR) Practices' at the 2024 Economic Times Awards
  • Achieved ISO 14001 and OHSAS 18001 certifications for its manufacturing facility
  • Consistently rated high for quality standards and ethical practices in KMPG’s independent pharma brand trust surveys
Market Information
NIFTY TOTAL MARKETNIFTY 500NIFTY SMLCAP 250NIFTY MIDSML 400NIFTY500 MULTICAP
ISIN INE182A01018
Sector Pharmaceuticals
IndustryPharmaceuticals
Company Timeline

74+ Years of Excellence | 7 Major Milestones

1950

Pfizer Ltd incorporated in India

1966

Listed on Bombay Stock Exchange

2000

Merged with Parke-Davis (India) Ltd

2014

Acquisition of Wyeth Ltd amalgamated business operations

2021

Launched COVID-19 therapies and vaccines in India in collaboration with the government

2023

Expanded digital engagement initiatives; invested in automation at Goa facility

2024

Recognized for ESG and leadership in ethical business conduct in the pharmaceutical sector

Coming Soon

The Next Evolution

Contact Information
Registered Office

1802/1901, The Capital, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (E)

Tel: 022-66932000,

Fax: 022-26540274,

Email: contactus.india@pfizer.com; prajeet.nair@pfizer.com

Website: pfizerltd.co.in

Registrars

KFin Technologies Ltd

Tel: 040 - 67161500 / 18003454001

Email: einward.ris@kfintech.com

Corporate Actions
18
PurposeEx DateRecord DateBC StartBC End
Final Dividend
₹75 per share
17 Jul 2026
Friday
17 Jul 2026
Friday
-
-
Final Dividend
₹35 per share
09 Jul 2025
Wednesday
09 Jul 2025
Wednesday
-
-
Special Dividend
₹130 per share
09 Jul 2025
Wednesday
09 Jul 2025
Wednesday
-
-
Final Dividend
₹35 per share
21 Aug 2024
Wednesday
21 Aug 2024
Wednesday
-
-
Special Dividend
₹5 per share
11 Aug 2023
Friday
11 Aug 2023
Friday
-
-
Final Dividend
₹35 per share
11 Aug 2023
Friday
11 Aug 2023
Friday
-
-
Special Dividend
₹30 per share
19 Sep 2022
Monday
20 Sep 2022
Tuesday
-
-
Dividend
₹35 per share
18 Aug 2022
Thursday
19 Aug 2022
Friday
-
-
Dividend
₹30 per share
11 Aug 2021
Wednesday
-
13 Aug 2021
Friday
19 Aug 2021
Thursday
Special Dividend
₹5 per share
11 Aug 2021
Wednesday
-
13 Aug 2021
Friday
19 Aug 2021
Thursday
Final Dividend
₹10 per share
27 Aug 2020
Thursday
-
29 Aug 2020
Saturday
04 Sep 2020
Friday
Special Dividend
₹320 per share
06 May 2020
Wednesday
08 May 2020
Friday
-
-
Final Dividend
₹22.50 per share
01 Aug 2019
Thursday
-
03 Aug 2019
Saturday
09 Aug 2019
Friday
Dividend
₹20 per share
29 Aug 2018
Wednesday
-
31 Aug 2018
Friday
06 Sep 2018
Thursday
Special Dividend
₹5 per share
22 Aug 2017
Tuesday
-
24 Aug 2017
Thursday
30 Aug 2017
Wednesday
Dividend
₹15 per share
22 Aug 2017
Tuesday
-
24 Aug 2017
Thursday
30 Aug 2017
Wednesday
Dividend
₹15 per share
27 Jun 2016
Monday
-
29 Jun 2016
Wednesday
05 Jul 2016
Tuesday
Dividend
₹12.50 per share
03 Jul 2015
Friday
-
07 Jul 2015
Tuesday
13 Jul 2015
Monday
Interim Dividend
Final Dividend
Dividend
Bonus
Split
Rights Issue
Other
.dsf..
Market Cap
₹21,428 Cr.
Curr. Price
₹4,665
52W High/Low
₹5,579 / 4,360
P/E (TTM)
29.15
Book Value
₹918.71
Price To Book Ratio
5.1
ROE
blog-img
ROE vs ROCE - Which Matters More for Evaluating Companies?
17.19 %
ROCE
blog-img
ROE vs ROCE - Which Matters More for Evaluating Companies?
41.64 %
EPS (TTM)
blog-img
What is EPS & what is its significance?
₹160.7
Face Value
₹10.00
Dividend Yield
1.6 %
Manage Ratio
11 ratios selected

Date Basis

Time Range

EPS
truewealth
Request an update
FINANCIALS
Revenue
-18.7%
2,569.8 Cr
3Y +16%
5Y -1%
HIST AVG
Operating Income
-17.0%
941.0 Cr
3Y +50%
5Y +18%
HIST AVG
Net Income
-19.3%
735.0 Cr
3Y +46%
5Y +25%
HIST AVG
EPS
-19.3%
160.0
3Y +48%
5Y +25%
HIST AVG
Op. Cash Flow
-27.7%
1,567.0 Cr
3Y +187%
5Y +59%
HIST AVG
PFIZER - Quarterly Results

Standalone Figures in Rs. Crores

Quarterly Results+Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026TTM
Income + - - - - - - - - 543 557 578 571 580 612 596 547 532 608 608 572 761 651 694 567 611 662 649 604 565 611 576 622 605 632 581 636 670 684 683 670 6980
Expenses + - - - - - - - - 401 408 378 403 405 431 432 425 359 425 428 440 493 476 510 422 431 435 448 420 439 411 408 378 402 416 408 384 411 429 433 410 4210
Profit + - - - - - - - - 92 96 132 109 113 154 139 103 124 131 141 101 200 143 144 126 33 311 151 130 94 149 130 179 151 158 128 331 192 189 142 200 2040
Tax +--------50536959622725194952393269324019111045035325246655257459568665069720
EPS + - - - - - - - - 20 21 29 24 25 34 30 23 27 29 31 22 44 31 31 28 7 68 33 28 20 33 27 22 33 35 28 72 42 41 31 44 450
Ratios +-
Cash Flow

Standalone Figures in Rs. Crores

Quarterly Cash FlowJun 2016

Sep 2016

Dec 2016

Mar 2017

Jun 2017

Sep 2017

Dec 2017

Mar 2018

Jun 2018

Sep 2018

Dec 2018

Mar 2019

Jun 2019

Sep 2019

Dec 2019

Mar 2020

Jun 2020

Sep 2020

Dec 2020

Mar 2021

Jun 2021

Sep 2021

Dec 2021

Mar 2022

Jun 2022

Sep 2022

Dec 2022

Mar 2023

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

-
Cash Flow Operating-----------------356-427-559-667-41-356-190-257-349-660-599-968--
Cash Flow Investing--------------------469--446--575-312--36--2-54--244--71--114--562--
Cash Flow Financing--------------------1,571--171--181--322--346--209--235--182--205--775--798--
Cash Increase Decrease-----------------356--1,613--57--88-31--26--21-75--77-383--290--392--
Net Cash And Cash Equivalent-----------------356-0.00-151-151-0.00-0.00-37-37-0.00-112-495-495--
Balance Sheet

Standalone Figures in Rs. Crores

Annual Balance Sheet+Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-
Assets + - - - 3,940 4,405 3,266 3,901 4,001 4,229 4,911 4,922-
Equity And Liabilities + - - - 3,940 4,405 3,266 3,901 4,001 4,229 4,911 4,922-
Shareholding Pattern

Numbers in Percentages

Quarterly SHP

Announcement Date

Jun 2016

30 Jun '16

Sep 2016

30 Sep '16

Dec 2016

31 Dec '16

Mar 2017

31 Mar '17

Jun 2017

30 Jun '17

Sep 2017

30 Sep '17

Dec 2017

31 Dec '17

Mar 2018

31 Mar '18

Jun 2018

12 Jul '18

Sep 2018

19 Nov '18

Dec 2018

12 Jan '19

Mar 2019

12 Apr '19

Jun 2019

20 Jul '19

Sep 2019

14 Oct '19

Dec 2019

10 Jan '20

Mar 2020

15 Apr '20

Jun 2020

14 Jul '20

Sep 2020

13 Oct '20

Dec 2020

12 Jan '21

Mar 2021

20 Apr '21

Jun 2021

19 Oct '21

Sep 2021

18 Oct '21

Dec 2021

12 Jan '22

Mar 2022

17 May '22

Jun 2022

02 Aug '22

Sep 2022

21 Oct '22

Dec 2022

10 Jan '23

Mar 2023

13 Apr '23

Jun 2023

20 Jul '23

Sep 2023

19 Oct '23

Dec 2023

02 Feb '24

Mar 2024

17 Apr '24

Jun 2024

20 Jul '24

Sep 2024

16 Oct '24

Dec 2024

20 Jan '25

Mar 2025

18 Apr '25

Jun 2025

15 Jul '25

Sep 2025

17 Oct '25

Dec 2025

16 Jan '26

Mar 2026

15 Apr '26

Jun 2026

16 Jul '26

-
Goverments ------------------------------------------
Promoter And Promoter Group - - - - - - - - 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92%-
Non Institutions --------20.49%20.48%20.10%19.90%19.66%19.69%19.36%19.73%19.16%19.18%19.89%19.55%18.86%18.86%18.92%18.82%18.70%18.65%18.38%18.38%18.37%18.25%17.90%17.42%17.01%16.50%16.54%16.79%16.45%16.37%16.32%16.37%16.63%-
FII - - - - - - - - - - - - - - - - - - - - - - - - - 2.55% 2.77% 2.80% 2.81% 2.82% 3.03% 3.33% 3.22% 3.54% 2.75% 2.18% 2.39% 2.60% 2.71% 2.81% 1.65%-
DII - - - - - - - - - - - - - - - - - - - - - - - - - 14.88% 14.93% 14.89% 14.89% 15.01% 15.15% 15.33% 15.84% 16.03% 16.79% 17.10% 17.23% 17.10% 17.05% 16.89% 17.80%-
Total --------100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%-

Pfizer Ltd

Pharmaceuticals
Last Updated: June 18, 2025

Pfizer Ltd

Pfizer Ltd is a leading pharmaceutical company in India and a subsidiary of the global Pfizer Inc. , headquartered in New York. Established in 1950, the company operates with a strong legacy of innovation and is focused on the development, manufacture, and marketing of prescription medicines across multiple therapeutic areas including cardiology, neurology, vaccines, oncology, and women’s health.

With its principal manufacturing facility located in Goa and a nationwide distribution and sales network, Pfizer Ltd has a well-entrenched presence in the Indian pharmaceutical sector, serving both private and public healthcare segments.

As one of India's prominent MNC pharma players, Pfizer Ltd leverages cutting-edge R&D from its global parent while maintaining a compliant and quality-focused approach to operations. The company's product portfolio features both globally patented medicines and several well-known legacy brands that hold leadership positions in their respective categories.

Pharmaceuticals SectorSince 1950
Business Model & Strategy

Pfizer Ltd generates revenues primarily through the marketing and sale of prescription pharmaceuticals. Its business model is built on in-licensing patented products from its parent and global affiliates, as well as the development and commercialization of branded generics tailored for the Indian market. The company emphasizes a robust distribution network, partnerships with healthcare professionals, and expansion into high-growth therapy segments like oncology and vaccines.

Strategic growth drivers include regular new product launches, driving market penetration of existing portfolios, digital engagement initiatives, and selective collaborations with other multinationals and local companies. Pfizer Ltd also maintains a focus on compliance, cost optimization, and operational efficiency to protect margins amid evolving regulatory and competitive landscapes.

Management Overview 8 Total Members
logo
Mr.Pradip Shah
Non-Executive - Non Independent Director-Chairperson
logo
Ms.Meena Ganesh
Non-Executive - Independent Director
logo
Mr.Lakshmanan Krishnakumar
Non-Executive - Independent Director
logo
Ms.Sonia Singh
Non-Executive - Independent Director
logo
Ms.Meenakshi Nevatia
Executive Director-CEO-MD
logo
Mr.Amit Agarwal
Executive Officer & Chief Financial Officer
logo
Mr.P Rengan
Executive Director
logo
PrajeetNair
Company Secretary and Compliance Officer
Awards & Recognition 5 Awards
Featured in ET 500 Top Companies 2024
Recognized as a 'Top Employer India 2024' by the Top Employers Institute
Received Silver in the 'Best Corporate Social Responsibility (CSR) Practices' at the 2024 Economic Times Awards
Achieved ISO 14001 and OHSAS 18001 certifications for its manufacturing facility
Consistently rated high for quality standards and ethical practices in KMPG’s independent pharma brand trust surveys
Market Information
Included In
NIFTY TOTAL MARKETNIFTY 500NIFTY SMLCAP 250NIFTY MIDSML 400NIFTY500 MULTICAP
Details
ISIN: INE182A01018
Sector: Pharmaceuticals
Industry: Pharmaceuticals
Company Timeline
74+ Years of Excellence
7 Major Milestones
1950
Pfizer Ltd incorporated in India
1966
Listed on Bombay Stock Exchange
2000
Merged with Parke-Davis (India) Ltd
2014
Acquisition of Wyeth Ltd amalgamated business operations
2021
Launched COVID-19 therapies and vaccines in India in collaboration with the government
2023
Expanded digital engagement initiatives; invested in automation at Goa facility
2024
Recognized for ESG and leadership in ethical business conduct in the pharmaceutical sector
Coming Soon: The Next Evolution
Contact Information
Registered Office
1802/1901, The Capital, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (E)
Tel: 022-66932000,
Fax: 022-26540274,
Email: contactus.india@pfizer.com; prajeet.nair@pfizer.com
Website: pfizerltd.co.in
Registrars
KFin Technologies Ltd
Tel: 040 - 67161500 / 18003454001
Email: einward.ris@kfintech.com

Peer Comparison

Part ofNIFTY TOTAL MARKETNIFTY 500NIFTY SMLCAP 250NIFTY MIDSML 400NIFTY500 MULTICAP
S.No.Company NameCMP (₹)Market Cap (₹ Cr)Div Yld (%)NP Qtr (₹ Cr)Qtr Profit Var (%)Sales Qtr (₹ Cr)Qtr Sales Var (%)ROCE (%)ROE (%)Book Value (₹)EPS TTM (₹)TTMPE Ratio (₹)
Not Found Data

Coming Soon

Heatmap View

Premium Feature
CompanyCMP (₹)MCap (₹ Cr)EPS TTM (₹)
Not Found Data

Financial Ratios

Premium Feature
Company NameP/E (TTM)EPS (₹)D/ENPMGPMROE (%)ROCE (%)P/B
Not Found Data

Coming Soon